Increased GABAergic function in mouse models of Huntington's disease: Reversal by BDNF

Huntington's disease (HD) is characterized by loss of striatal γ‐aminobutyric acid (GABA)ergic medium‐sized spiny projection neurons (MSSNs), whereas some classes of striatal interneurons are relatively spared. Striatal interneurons provide most of the inhibitory synaptic input to MSSNs and use GABA as their neurotransmitter. We reported previously alterations in glutamatergic synaptic activity in the R6/2 and R6/1 mouse models of HD. In the present study, we used whole‐cell voltage clamp recordings to examine GABAergic synaptic currents in MSSNs from striatal slices in these two mouse models compared to those in age‐matched control littermates. The frequency of spontaneous GABAergic synaptic currents was increased significantly in MSSNs from R6/2 transgenics starting around 5–7 weeks (when the overt behavioral phenotype begins) and continuing in 9–14‐week‐old mice. A similar increase was observed in 12–15‐month‐old R6/1 transgenics. Bath application of brain‐derived neurotrophic factor, which is downregulated in HD, significantly reduced the frequency of spontaneous GABAergic synaptic currents in MSSNs from R6/2 but not control mice at 9–14 weeks. Increased GABA current densities also occurred in acutely isolated MSSNs from R6/2 animals. Immunofluorescence demonstrated increased expression of the ubiquitous α1 subunit of GABAA receptors in MSSNs from R6/2 animals. These results indicate that increases in spontaneous GABAergic synaptic currents and postsynaptic receptor function occur in parallel to progressive decreases in glutamatergic inputs to MSSNs. In conjunction, both changes will severely alter striatal outputs to target areas involved in the control of movement. © 2004 Wiley‐Liss, Inc.

[1]  W. Sieghart,et al.  Functional Correlation of GABAA Receptor α Subunits Expression with the Properties of IPSCs in the Developing Thalamus , 2000, The Journal of Neuroscience.

[2]  J. Benson,et al.  BDNF reduces miniature inhibitory postsynaptic currents by rapid downregulation of GABAA receptor surface expression , 2001, The European journal of neuroscience.

[3]  H. Parthasarathy,et al.  Local Release of GABAergic Inhibition in the Motor Cortex Induces Immediate-Early Gene Expression in Indirect Pathway Neurons of the Striatum , 1997, The Journal of Neuroscience.

[4]  R. Mckernan,et al.  Which GABAA-receptor subtypes really occur in the brain? , 1996, Trends in Neurosciences.

[5]  J. Tepper,et al.  Inhibitory control of neostriatal projection neurons by GABAergic interneurons , 1999, Nature Neuroscience.

[6]  A. Morton,et al.  Mice transgenic for the human Huntington’s disease mutation have reduced sensitivity to kainic acid toxicity , 2000, Brain Research Bulletin.

[7]  S. Moss,et al.  Molecular Brain-Derived Neurotrophic Factor Modulates Fast Synaptic Inhibition by Regulating GABAA Receptor Phosphorylation , Activity , and Cell-Surface Stability , 2004 .

[8]  J. Bargas,et al.  Dopamine selects glutamatergic inputs to neostriatal neurons , 1997, Synapse.

[9]  J. Alberch,et al.  Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington’s disease , 2002, Brain Research Bulletin.

[10]  J. Bargas,et al.  Cellular and molecular characterization of Ca2+ currents in acutely isolated, adult rat neostriatal neurons , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[12]  S. Gauthier,et al.  Human CSF GABA Concentrations: Revised Dowd for Controls, but Not Decreased in Huntington's Chorea , 1982, Journal of neurochemistry.

[13]  M. Chesselet,et al.  Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. , 2001, Journal of neurophysiology.

[14]  J. Tepper,et al.  Dual Cholinergic Control of Fast-Spiking Interneurons in the Neostriatum , 2002, The Journal of Neuroscience.

[15]  J. Bolam,et al.  Selective Innervation of Neostriatal Interneurons by a Subclass of Neuron in the Globus Pallidus of the Rat , 1998, The Journal of Neuroscience.

[16]  D. Plenz When inhibition goes incognito: feedback interaction between spiny projection neurons in striatal function , 2003, Trends in Neurosciences.

[17]  J. Waddington,et al.  Therapeutic failure of GABA agonist treatment in Huntington's disease , 1984, Neurology.

[18]  S. W. Davies,et al.  Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  O. Hansson,et al.  Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice , 2001, The European journal of neuroscience.

[20]  A. Hartmann,et al.  Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic mice , 2003, Journal of neurochemistry.

[21]  Fabrice P Cordelières,et al.  Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.

[22]  M. Charlton,et al.  Huntington'S disease: Treatment with muscimol, A GABA‐mimetic drug , 1978, Annals of neurology.

[23]  Postnatal development of a persistent Na+ current in pyramidal neurons from rat sensorimotor cortex. , 1993, Journal of neurophysiology.

[24]  A. Morton,et al.  Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation , 1999, The Journal of Neuroscience.

[25]  Joseph B. Martin Huntington's disease , 1984, Neurology.

[26]  H. Lester,et al.  Enhancement of Neurotransmitter Release Induced by Brain-Derived Neurotrophic Factor in Cultured Hippocampal Neurons , 1998, The Journal of Neuroscience.

[27]  C. Cepeda,et al.  Persistent Na+ conductance in medium-sized neostriatal neurons: characterization using infrared videomicroscopy and whole cell patch-clamp recordings. , 1995, Journal of neurophysiology.

[28]  S B Dunnett,et al.  Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation , 2000, The Journal of Neuroscience.

[29]  T. Hare,et al.  Huntington's disease. Cerebrospinal fluid GABA levels in at-risk individuals. , 1978, Archives of neurology.

[30]  C. Cepeda,et al.  Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. , 1998, Journal of neurophysiology.

[31]  A. Leslie Morrow,et al.  GABAA Receptor α1 Subunit Deletion Prevents Developmental Changes of Inhibitory Synaptic Currents in Cerebellar Neurons , 2001, The Journal of Neuroscience.

[32]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Tobin,et al.  Huntington's disease: the challenge for cell biologists. , 2000, Trends in cell biology.

[34]  F. Fujiyama,et al.  Synaptic localization of GABAA receptor subunits in the striatum of the rat , 2000, The Journal of comparative neurology.

[35]  T. Verdoorn Formation of heteromeric gamma-aminobutyric acid type A receptors containing two different alpha subunits. , 1994, Molecular pharmacology.

[36]  D. Overstreet,et al.  Benzodiazepine receptors: The effect of GABA on their characteristics in human brain and their alteration in Huntington's disease , 1980, Brain Research.

[37]  E. Arenas,et al.  Brain‐Derived Neurotrophic Factor, Neurotrophin‐3, and Neurotrophin‐4/5 Prevent the Death of Striatal Projection Neurons in a Rodent Model of Huntington's Disease , 2000, Journal of neurochemistry.

[38]  N. Matsuki,et al.  Inhibition of GABAA Synaptic Responses by Brain-Derived Neurotrophic Factor (BDNF) in Rat Hippocampus , 1997, The Journal of Neuroscience.

[39]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[40]  G. Graveland,et al.  Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. , 1985, Science.

[41]  Stephen B. Dunnett,et al.  Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington’s Disease Mutation , 1999, The Journal of Neuroscience.

[42]  M. Hamann,et al.  Effects of striatal injections of GABA(A) receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia. , 2002, European journal of pharmacology.

[43]  C. Cepeda,et al.  NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.

[44]  W. Robberecht,et al.  Chloride Influx Aggravates Ca2+-Dependent AMPA Receptor-Mediated Motoneuron Death , 2003, The Journal of Neuroscience.

[45]  A. Reiner,et al.  Can lesions of GPe correct HD deficits? , 2004, Experimental Neurology.

[46]  Enrico Bracci,et al.  Dopamine excites fast-spiking interneurons in the striatum. , 2002, Journal of neurophysiology.

[47]  Carlos Cepeda,et al.  Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.

[48]  J. Penney,et al.  Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis , 1995, Neuroscience.

[49]  D. Joel,et al.  Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus , 2004, Experimental Neurology.

[50]  E. Richfield,et al.  Reduced expression of preproenkephalin in striatal neurons from huntington's disease patients , 1995, Annals of neurology.

[51]  H. C. Cromwell,et al.  Neocortical damage alters synaptic responses of neostriatal neurons in vitro , 1996, Neuroscience.

[52]  O. Hansson,et al.  Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[53]  K. Leenders,et al.  Benzodiazepine receptor binding in Huntington's disease: [11C]Flumazenil uptake measured using positron emission tomography , 2000, Annals of neurology.

[54]  Carlos Cepeda,et al.  Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.

[55]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[56]  B. Harper Huntington Disease , 2005, Journal of the Royal Society of Medicine.

[57]  D. Plenz,et al.  Up and Down States in Striatal Medium Spiny Neurons Simultaneously Recorded with Spontaneous Activity in Fast-Spiking Interneurons Studied in Cortex–Striatum–Substantia Nigra Organotypic Cultures , 1998, The Journal of Neuroscience.

[58]  S. W. Davies,et al.  Brain Neurotransmitter Deficits in Mice Transgenic for the Huntington’s Disease Mutation , 1999, Journal of neurochemistry.

[59]  T. Perry,et al.  Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. , 1973, The New England journal of medicine.

[60]  A. Parent,et al.  Striatal interneurons in Huntington's disease: Selective increase in the density of calretinin‐immunoreactive medium‐sized neurons , 1996, Movement disorders : official journal of the Movement Disorder Society.

[61]  B. Hutcheon,et al.  Organization of GABAA receptor α‐subunit clustering in the developing rat neocortex and hippocampus , 2004, The European journal of neuroscience.

[62]  GABA is toxic for mouse striatal neurones through a transporter‐mediated process , 2002, Journal of neurochemistry.

[63]  J. Penney,et al.  Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. , 1999, Journal of neuropathology and experimental neurology.

[64]  J. Penney,et al.  Benzodiazepine and GABA receptors in early Huntington's disease , 1984, Neurology.

[65]  E. Bird,et al.  Alterations in 3H-GABA binding in Huntington's chorea. , 1977, Life sciences.

[66]  G Bernardi,et al.  GABA depolarizes neurons in the rat striatum: An in vivo study , 1991, Synapse.

[67]  T. Kosaka,et al.  Parvalbumin is expressed in glutamatergic and GABAergic corticostriatal pathway in mice , 2004, The Journal of comparative neurology.

[68]  D. Sibley,et al.  Striatal neurochemical changes in transgenic models of Huntington's disease , 2002, Journal of neuroscience research.

[69]  Carlos Cepeda,et al.  Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect , 2004, Trends in Neurosciences.

[70]  K. Lloyd,et al.  [3H]GABA binding in brains from Huntington's chorea patients: altered regulation by phospholipids? , 1979, Science.

[71]  M. Chesselet,et al.  Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington’s Disease , 2000, Experimental Neurology.

[72]  J. Penney,et al.  Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study , 2004, Journal of Chemical Neuroanatomy.

[73]  Hui Zhang,et al.  Heterosynaptic Dopamine Neurotransmission Selects Sets of Corticostriatal Terminals , 2004, Neuron.

[74]  J. Deniau,et al.  Synaptic Convergence of Motor and Somatosensory Cortical Afferents onto GABAergic Interneurons in the Rat Striatum , 2002, Journal of Neuroscience.

[75]  A M Graybiel,et al.  Cortically Driven Immediate-Early Gene Expression Reflects Modular Influence of Sensorimotor Cortex on Identified Striatal Neurons in the Squirrel Monkey , 1997, The Journal of Neuroscience.